24 Jul 2026
Marc N. Wagner Joins Fox Rothschild in Washington, DC as Partner for FDA and Life Sciences Regulatory Practice
"Fox Rothschild adds Marc N. Wagner as a Partner in Washington, DC to bolster its FDA and life sciences regulatory practice, focusing on FDA and DEA compliance, enforcement and transactional matters."
Wagner advises pharmaceutical, biotechnology, medical device, dietary supplement, food and healthcare companies on a broad range of FDA and DEA regulatory compliance, enforcement and transactional matters. His practice spans the full product lifecycle, from development and commercialization through inspections, investigations and post-market compliance. He represents pharmaceutical manufacturers, outsourcing facilities, compounding pharmacies, wholesale distributors, third-party logistics providers, healthcare providers and other regulated entities in matters involving FDA and DEA compliance obligations and regulatory enforcement.
He regularly represents clients in government investigations and enforcement matters involving the FDA, DEA, the Department of Justice, state attorneys general and state regulatory agencies, and guides companies through inspections, import detentions, warning letters, product seizures, injunction actions and other regulatory proceedings. Wagner also advises private equity sponsors, strategic investors and life sciences companies on mergers, acquisitions, divestitures and other strategic transactions.
A former licensed pharmacist, Wagner combines legal, regulatory and industry experience to assist clients with complex compliance and business challenges. He earned his J.D. from Pennsylvania State University Dickinson School of Law, his M.B.A. from Pennsylvania State University, and his Pharm.D. and B.S. from the University of the Sciences Philadelphia College of Pharmacy. Prior to joining Fox Rothschild, Wagner was an attorney with BakerHostetler.